Atopic dermatitis and inflammatory skin disease Treatment of atopic dermatitis with tralokinumab , an anti – IL-13 mAb

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of lebrikizumab (an anti‐IL‐13 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo‐controlled phase II trial (TREBLE)

  2018cited by this paper
• Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis

  2017cited by this paper
• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

  2017cited by this paper
• An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease.

  2017cited by this paper
• Targeting the T Helper 2 Inflammatory Axis in Atopic Dermatitis

  2016cited by this paper
• Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

  2016cited by this paper
• Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

  2016cited by this paper
• ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients

  2016cited by this paper
• Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

  2016cited by this paper
• A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis.

  2016cited by this paper
• Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

  2015cited by this paper
• Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.

  2015cited by this paper
• Drug evaluation review: dupilumab in atopic dermatitis.

  2015cited by this paper
• Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

  2015cited by this paper
• Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease.

  2014cited by this paper
• Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.

  2014cited by this paper
• Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

  2014cited by this paper
• Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches.

  2014cited by this paper
• Periostin in allergic inflammation.

  2014cited by this paper
• Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

  2014cited by this paper
• Periostin, a novel biomarker of TH2-driven asthma

  2014cited by this paper
• Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence.

  2014cited by this paper
• Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

  2014cited by this paper
• Dupilumab in persistent asthma with elevated eosinophil levels

  2013cited by this paper
• Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis.

  2012cited by this paper
• A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

  2012cited by this paper
• Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

  2012influential reference
• EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference

  2012cited by this paper
• Covariate-Adjusted Difference in Proportions from Clinical Trials Using Logistic Regression and Weighted Risk Differences

  2011cited by this paper
• Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response.

  2011cited by this paper
• An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.

  2010cited by this paper
• A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

  2010cited by this paper
• Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis

  2004cited by this paper
• Cytokine Milieu of Atopic Dermatitis, as Compared to Psoriasis, Skin Prevents Induction of Innate Immune Response Genes 1

  2003cited by this paper

• Peripheral Blood Skin‐Homing T Cells Define Immunological Endotypes in Atopic Dermatitis: A Case–Control Study in a Mexican Population

  2026cites this paper
• Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis

  2026cites this paper
• Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review

  2026cites this paper
• From neuroimmune circuits to targeted therapy of chronic pruritus

  2026cites this paper
• Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity.

  2026cites this paper
• Effectiveness of Anti-IL-13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48-Week Outcomes by Lebrikizumab and Tralokinumab.

  2026cites this paper
• Postmarketing adverse events of biologics and Janus kinase inhibitors in patients with atopic dermatitis.

  2026cites this paper
• Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

  2026cites this paper
• Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review.

  2026cites this paper
• Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study

  2025cites this paper
• Increasing dosing intervals for biologics in atopic dermatitis‐why, who, when and how?

  2025cites this paper
• Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy.

  2025cites this paper
• Genetic and Epigenetic Interconnections Between Atopic Dermatitis, Allergic Rhinitis, and Rhinitis with Nasal Polyps

  2025cites this paper
• Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?

  2025cites this paper
• Skin care knowledge, attitudes and practices: a comparative study between patients with atopic dermatitis and healthy individuals

  2025cites this paper
• The Single-Cell Atlas Reveals Subset-Specific Transcriptional Programs of NK Cells in Skin Inflammation.

  2025cites this paper
• Drug Utilization and Medication Adherence: A Data-Driven Analysis of Drugs with Different Routes of Administration Applied in Atopic Dermatitis

  2025cites this paper
• Efficacy and Safety of All Monoclonal Antibodies in Moderate‐to‐Severe Atopic Dermatitis: A Systematic Review and Network Meta‐Analysis

  2025cites this paper
• Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies

  2025cites this paper
• Transcriptomic analysis of skin biopsies in Prurigo nodularis patients: with and without atopic dermatitis

  2025cites this paper
• Manejo clínico da dermatite atópica: uma revisão integrativa da literatura

  2025cites this paper
• Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

  2025cites this paper
• Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice

  2025cites this paper
• Immunoassay-based biomarkers in atopic dermatitis.

  2025cites this paper
• Advancing Precision Medicine in Inflammatory Skin Disease

  2025cites this paper
• Medicina de precisão e abordagens Treat‐to‐Target na dermatite atópica: melhorando o atendimento personalizado e os resultados

  2025cites this paper
• Biomarkers in Atopic Dermatitis in Children: A Comprehensive Review

  2025cites this paper
• Enabling precision medicine with biomarkers of response to treatment in atopic dermatitis: where are we now? A narrative review

  2025influential citation
• Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis

  2025cites this paper
• Precision medicine and Treat-to-Target approach in atopic dermatitis: enhancing personalized care and outcomes

  2025cites this paper
• Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment

  2025cites this paper
• The role of type 2 inflammation in the pathogenesis of atopic dermatitis

  2025cites this paper
• Innovative microbial strategies in atopic dermatitis

  2025cites this paper
• Lack of Evidence for the Efficacy of Antifungal Medications to Treat Atopic Dermatitis: A Systematic Review

  2024cites this paper
• Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions

  2024cites this paper
• Terapia direcionada para doenças imunomediadas da pele. O que o dermatologista deve saber?

  2024cites this paper
• Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration

  2024cites this paper
• Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system

  2024cites this paper
• Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study

  2024cites this paper
• Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab

  2024influential citation
• A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis

  2024cites this paper
• Prurit et douleur cutanée au cours de la dermatite atopique

  2024cites this paper
• Pruritus in the Elderly: Differential Diagnosis and Management

  2024cites this paper
• [[Translated article]]RF-Personalized Medicine to Treat Atopic Dermatitis: In Search for Predictive Biomarkers.

  2024cites this paper
• Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond

  2024influential citation
• Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling

  2024cites this paper
• Should Emollients Be Recommended for the Prevention of Atopic Dermatitis?—New Evidence and Current State of Knowledge

  2024cites this paper
• Targeted therapy for immune mediated skin diseases. What should a dermatologist know?

  2024cites this paper
• Emerging Systemic Treatment Options in Atopic Dermatitis

  2024cites this paper
• Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data

  2024cites this paper
• Molecular and cellular mechanisms of itch sensation and the anti-itch drug targets

  2024cites this paper
• Addressing Unmet Needs in Atopic Dermatitis: Evaluating Disease-Modifying Capabilities of Current and Emerging Therapies

  2024cites this paper
• IL-13 inhibition in the treatment of atopic dermatitis – new and emerging biologic agents

  2024cites this paper
• The search for blood biomarkers useful in treating atopic dermatitis patients

  2024cites this paper
• Cendakimab in Patients With Moderate to Severe Atopic Dermatitis

  2024cites this paper
• A systematic review investigating the proportion of clinical images shared in prospective randomized controlled trials involving patients with atopic dermatitis and systemic pharmacotherapy

  2024cites this paper
• Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease

  2024cites this paper
• Innovative Immunotherapy for the Treatment of Atopic Dermatitis: Focus on the European and Latin American Regulatory Frameworks

  2024cites this paper
• A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index.

  2024cites this paper
• Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain

  2024cites this paper
• Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment

  2024cites this paper
• Systemic Immunomodulatory Treatments for Atopic Dermatitis

  2024cites this paper
• Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

  2024cites this paper
• Interleukin antagonists for atopic dermatitis: a new era of therapy

  2024cites this paper
• Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments

  2023cites this paper
• Netherton syndrome in a Bulgarian patient

  2023cites this paper
• Targeting Interleukin 13 for the Treatment of Atopic Dermatitis

  2023cites this paper
• Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis

  2023cites this paper
• Real‐life case‐series experience with tralokinumab in patients with severe atopic dermatitis

  2023cites this paper
• A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults

  2023cites this paper
• Dupilumab induced ocular surface disease: A prospective case series

  2023cites this paper
• Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases

  2023cites this paper
• The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents.

  2023cites this paper
• Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents

  2023cites this paper
• [Algoritmo de tratamiento de la dermatitis atópica en Perú. Consenso de expertos].

  2023cites this paper
• Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis

  2023cites this paper
• Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade

  2023cites this paper
• A Mini Review of the Impact of Baseline Disease Severity on Clinical Outcomes: Should We Compare Atopic Dermatitis Clinical Trials?

  2023cites this paper
• Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Editorial: Cutaneous immunology

  2023cites this paper
• Clinical trials of antibody drugs in the treatments of atopic dermatitis

  2023cites this paper
• How Do Classical Subtypes Correspond to Endotypes in Atopic Dermatitis?

  2023cites this paper
• Aiming to IgE: Drug development in allergic diseases.

  2023cites this paper
• Atopic dermatitis: a brief review of recent advances in management

  2023cites this paper
• Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape‐strips and biopsies

  2023cites this paper
• Atopic Dermatitis in the Adult Population

  2023cites this paper
• 中等症から重症の日本人成人アトピー性皮膚炎患者におけるトラロキヌマブの単独療法およびステロイド外用薬併用療法の有効性と安全性の検討

  2023cites this paper
• Cytokine-targeted treatment in alopecia areata - new possibilities?

  2023cites this paper
• Genomic profiling of the overlap phenotype between psoriasis and atopic dermatitis.

  2023cites this paper
• Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis

  2023influential citation
• Design and Evaluation of Dissolvable Microneedles for Treating Atopic Dermatitis

  2023cites this paper
• Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition

  2023cites this paper
• Interleukin‐21 in autoimmune and inflammatory skin diseases

  2023cites this paper
• Biomarkers in atopic dermatitis.

  2023cites this paper
• Targeting IgE and Th2-Cytokines in Allergy: Brief Updates on Monoclonal Antibodies and Antibody Gene Therapy

  2023cites this paper
• Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report

  2022cites this paper
• Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis

  2022cites this paper
• Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report

  2022cites this paper
• Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis

  2022cites this paper
• Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management

  2022cites this paper